Congenital and neonatal cytomegalovirus infection in pre-term neonates
Abstract number: P1483
Gonzalez Barbera E.M., Acosta Boga B., Cernada Badia M., Rosingh A.W., Cordoba Cortijo J., Gobernado M.
Objectives: To study the incidence of congenital or neonatal cytomegalovirus (CMV) infection children hospitalized in the Neonatology unit of a tertiary care hospital during the period January 2006October 2009.
Methods: A prospective observational study was carried out in the Neonatology unit including neonates with a birth weight 1.500 g. or signs/symptoms compatible with CMV infection.
Congenital (CMV positive result in the two first weeks of life) and neonatal CMV infection were identified through urine shell-vial culture [MRC5 cell line (Vircell), CMV monoclonal antibody stain (Chemicon)] and/or plasma CMV viral load [artus CMV LC PCR Kit (Qiagen)]. We studied 1591 urine samples by shell-vial culture and 178 plasma samples by CMV viral load from 894 neonates. The same techniques were used for follow-up study (and in some cases we also carried out a CMV maternal study). We also collected data about blood transfusions in these patients.
Results: Fifty-three (5.93%) neonates were diagnosed with cytomegalovirus infection. Fourteen of them (26.41%) were considered congenital, in seven infants (13.20%) we couldn't distinguish between congenital or perinatal infection and thirty-two children (60.38%) were considered perinatal infection. Of them, in 16 cases the breast milk was studied for CMV presence (shell-vial/viral load) finding ten positive results.
All children except two with perinatal infection received blood products (one with shell-vial positive result of breast milk).
Conclusion: In our study neonatal CMV infection is frequent in preterm infants. The role of breast feeding is important in perinatal transmission (10 positive results/16 studied cases), but most of them (30/32) had been exposed to other transmission routes, such as the use of blood products.
CMV urine shell-vial culture is a good and non invasive test for screening, but not for follow-up patients. CMV plasma viral load could be the best choice for following up on these patients.
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|